Capricor Therapeutics, Inc. (FRA:4LN2)

Market Cap	1.25B +100.1%
Revenue (ttm)	9.49M -52.1%
Net Income	-69.88M
EPS	-1.54
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	19.02
Previous Close	18.54
Day's Range	18.86 - 19.06
52-Week Range	3.73 - 26.05
Beta	n/a
RSI	46.33
Earnings Date	Feb 27, 2026

About Capricor Therapeutics

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 160
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4LN2

Financial Performance

In 2024, Capricor Therapeutics's revenue was $22.27 million, a decrease of -11.55% compared to the previous year's $25.18 million. Losses were -$40.47 million, 81.6% more than in 2023.

Financial numbers in USD